IPCALAB - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.8
| Stock Code | IPCALAB | Market Cap | 39,220 Cr. | Current Price | 1,544 ₹ | High / Low | 1,624 ₹ |
| Stock P/E | 39.0 | Book Value | 292 ₹ | Dividend Yield | 0.26 % | ROCE | 17.6 % |
| ROE | 12.6 % | Face Value | 1.00 ₹ | DMA 50 | 1,489 ₹ | DMA 200 | 1,434 ₹ |
| Chg in FII Hold | 0.20 % | Chg in DII Hold | 0.54 % | PAT Qtr | 303 Cr. | PAT Prev Qtr | 305 Cr. |
| RSI | 57.8 | MACD | 21.6 | Volume | 4,58,188 | Avg Vol 1Wk | 4,77,959 |
| Low price | 1,168 ₹ | High price | 1,624 ₹ | PEG Ratio | -53.5 | Debt to equity | 0.11 |
| 52w Index | 82.5 % | Qtr Profit Var | 13.4 % | EPS | 31.7 ₹ | Industry PE | 27.2 |
📊 Ipca Laboratories (IPCALAB) shows moderately favorable conditions for swing trading. The RSI at 57.8 indicates neutral momentum, while the MACD (21.6) is positive, suggesting bullish signals. The stock is trading above both its 50 DMA (1,489 ₹) and 200 DMA (1,434 ₹), which reflects strength. The optimal entry price would be around 1,500–1,520 ₹. If already holding, consider exiting near 1,600–1,620 ₹, close to the 52-week high, unless momentum continues strongly.
✅ Positive
- Strong ROCE (17.6%) and ROE (12.6%) indicate efficient capital use.
- Low debt-to-equity ratio (0.11) ensures financial stability.
- EPS of 31.7 ₹ shows consistent earnings power.
- Institutional confidence with FII (+0.20%) and DII (+0.54%) holdings increasing.
⚠️ Limitation
- High P/E ratio (39.0) compared to industry average (27.2).
- PEG ratio (-53.5) suggests poor valuation alignment with growth.
- Dividend yield of 0.26% is modest.
- Quarterly PAT nearly flat (303 Cr. vs. 305 Cr.).
📉 Company Negative News
- Profit growth stagnated in the latest quarter.
- Valuation appears stretched relative to industry peers.
📈 Company Positive News
- Quarterly profit variation of 13.4% shows underlying growth momentum.
- Strong institutional inflows (FII and DII increases).
- Stock trading near 52-week high, reflecting investor confidence.
🏭 Industry
- Industry PE at 27.2 vs. IPCALAB’s PE of 39.0 suggests overvaluation.
- Pharmaceutical sector remains resilient with steady demand.
🔎 Conclusion
Ipca Laboratories has strong fundamentals and positive technical signals, making it a moderately good candidate for swing trading. Entry near 1,500–1,520 ₹ could be favorable. Exit strategy should target 1,600–1,620 ₹ unless momentum continues. Long-term investors may hold for sectoral resilience, while short-term traders should monitor valuation risks.